Provectus Pharmaceuticals Inc. Adds Second Center to Phase 2 Clinical Trial of PV-10

KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com) has begun recruitment for its Phase 2 clinical trial of the Company’s lead oncology agent PV-10 (also known as Provecta) at a second major center, now covering Brisbane, Australia in addition to Sydney, Australia. Over the next several months, the Company expects to continue expansion of the study to include sites in most major population centers in Australia as well as several sites in the United States.

Back to news